Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes
Clinical Pharmacology & Therapeutics · 2026
DOI: 10.1002/cpt.70381 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Joseph H Breeyear und 16 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Computational Biology Branch, National Institute for Environmental Health Sciences, National Institutes of Health, Durham, North Ca…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sulfonylurea Compounds, Hypoglycemic Agents. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Novo Nordisk, NIEHS NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Sulfonylureas are a cornerstone of type 2 diabetes therapy despite interindividual variability in response. Despite well‐documented sex‐based differences, pharmacogenomic and genome‐wide association studies (GWAS) have largely overlooked sex as a biological variable. We conducted the first sex‐stratified GWAS of hemoglobin A1c (HbA1c) response to sulfonylureas in Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial participants ( N = 871). Variants meeting genome‐wide ( P < 5.0 × 10 –8 ) and suggestive ( P < 5.0 × 10 –6 ) significance were assessed for replication in the Pharmacogenomics of Metformin (PMET1) cohort. Replicated variants were further analyzed in the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR‐MGH) cohort to assess acute insulin and glucose responses to a single glipizide dose. Genome‐wide significant loci with sex‐specific effects were identified: KAZN , KIF2B , SLC39A10 , and SPINK5 (combined‐sex); CRACR2A , KCNK2 , and TENM2 (male‐only); and NACPH2 (female‐only). Two suggestive variants in the TMEM64 / NECAB1 locus, associated with reduced HbA1c response to sulfonylureas in the male‐only ACCORD analysis, were directly replicated in the PMET1 male‐only cohort. In SUGAR‐MGH, one replicated variant (rs6471250‐C) was significantly associated with reduced peak insulin in males ( P = 0.035) but not females ( P = 0.40), demonstrating sex‐specific functional effects. This study identified statistically supported and biologically plausible loci with prior evidence linking nearby genes to pathways relevant to sulfonylurea action, including insulin secretion, insulin regulation/sensitivity, calcium signaling, potassium‐channel biology, and glucose transport. The findings highlight sex‐specific differences in sulfonylurea response, providing mechanistic insights and underscoring the importance of sex‐specific precision medicine. Identification of genetic variants influencing sex‐specific response could inform dosing to optimize sulfonylureas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biostatistics and Computational Biology Branch, National Institute for Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, USA.
- Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
- Joslin Diabetes Center and Harvard Medical School, Boston, Massachusetts, USA.
- Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
ORCID-Profile: Joseph H Breeyear, John S House, Mark Kvale, Kathleen M Giacomini, Josyf C Mychaleckyj, Josephine H Li, Sook Wah Yee, Alison A Motsinger-Reif
Förderung
- NHLBI NIH HHS
- Novo Nordisk
- NIEHS NIH HHS
- NIGMS NIH HHS
- NIDDK NIH HHS
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Environmental Health Sciences
Zitieren
APA
Breeyear, J. H., House, J. S., Kvale, M., Nam, S., Akhtari, F. S., Shah, H. S., Hedderson, M. M., Giacomini, K. M., Mychaleckyj, J. C., Doria, A., Wagner, M. J., Li, J. H., Yee, S. W., Buse, J. B., Woychik, R. P., Rotroff, D. M., & Motsinger-Reif, A. A. (2026). Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70381
Vancouver
Breeyear JH, House JS, Kvale M, Nam S, Akhtari FS, Shah HS, et al. Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70381
BibTeX
@article{Breeyear2026,
author = {Breeyear, Joseph H and House, John S and Kvale, Mark and Nam, Stella and Akhtari, Farida S and Shah, Hetal S and Hedderson, Monique M and Giacomini, Kathleen M and Mychaleckyj, Josyf C and Doria, Alessandro and Wagner, Michael J and Li, Josephine H and Yee, Sook Wah and Buse, John B and Woychik, Richard P and Rotroff, Daniel M and Motsinger-Reif, Alison A},
title = {Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
doi = {10.1002/cpt.70381}
}
EUVIMED